Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.
The new trial has enrolled its first patient.
Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the ACTIV-4 Host Tissue trial will first explore the efficacy of drugs that target the Renin Angiotensin Aldosterone System (RAAS) and the immune system, both of which become dysregulated during COVID-19 and cause widespread damage in patients infected with the SARS-CoV-2 virus.